Altasciences CEO Chris Perkin has gone through several acquisitions in his 45-year career. And if there’s one thing he learned, it’s how not to go through an acquisition. His company put that…
Amid the spike in positive Covid-19 cases thanks to the Omicron variant, Ascletis will expand its production of the oral tablet ritonavir to produce 100 million doses a year. And the company is ready…
As the FDA is looking to reduce drug shortages further by collecting more data on the volume of drugs and APIs manufactured worldwide, companies like Pfizer, Thermo Fisher, Viatris and industry groups…
A group of institutional investors from Nomura, BMO, GAM and more than 60 others representing trillions in assets are now calling on Covid-19 vaccine developers to link their executives’ pay to ensure…
California has become the first state to require health insurance plans to cover at-home tests for sexually transmitted infections such as HIV, chlamydia and syphilis.
Stryker has inked a $3 billion deal to dramatically reshape its digital patient outreach efforts with the acquisition of Vocera Communications.
Sanofi is getting deeper into AI-driven R&D. After working with AI drug discovery shop Exscientia for five years, Sanofi has significantly expanded its relationship, putting up $100 million and $5.2…
Aligos went public back in October 2020, with $40 million of its overall haul going toward its hepatitis B antiviral ‘STOPS’ medicine. But now, what’s stopping is the drug’s development.
Amgen wants its future drugs to be multispecific, and so the biopharmaceutical company selected Generate Biomedicines for a $1.9 billion biobucks deal to initially create five programs across several…
Sanofi is rethinking its approach to genomic medicines. Having worked with Sangamo Therapeutics on personalized cell therapies, Sanofi has decided to scrap the deal and shift its focus to allogeneic…
